Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for obese/overweight type 2 diabetes mellitus with comorbid depression
ChiCTR2400088178Phase 4Not yet recruiting
- Sponsor
- Chengdu Shuangliu District Traditional Chinese Medicine Hospital
- Start
- Aug 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of liraglutide in type 2 diabetes mellitus (T2DM), major depressive disorder (MDD), obesity and 1 more (2 arms), sponsored by Chengdu Shuangliu District Traditional Chinese Medicine Hospital. Primary endpoints: Blood sugar, HbA1c and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)major depressive disorder (MDD)obesityOverweight
Beyond the preview
Go deeper on ChiCTR2400088178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088178.